Jim Hoffman: Could Extracorporeal Removal of NETs Become a ‘Holy Grail’ Therapy Across Multiple Diseases?
Jim Hoffman, Former Technical Advisor at Cygnus Technologies, LLC, shared a post on LinkedIn about a recent article by Michal Santocki and Elzbieta Kolaczkowska, published in Cells:
“Could extracorporeal removal of NETs and other extracellular chromatin outperform many drug treatments with the potential to be a holy grail treatment for multiple diseases and disorders, slowing their progression and aiding recovery, largely free of systemically administered drug-related side effects?
Recent evidence, courtesy of Santersus AG, treating severe Lupus, and backed by over two decades of NETosis research, suggests we should pay much more attention to the universal potential of this therapy to transform disease management, since dysregulated NETosis contributes to the progression of most, if not all, diseases.”
Title: On Neutrophil Extracellular Trap (NET) Removal: What We Know Thus Far and Why So Little
Authors: Michal Santocki, Elzbieta Kolaczkowska
Read the Full Article on Cells.
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 17, 2026, 04:07Weihao Li: Global HEPATIC Registry Findings on Post-Transplant Arterial Thrombosis
-
Oct 17, 2026, 03:56Ghaith Abu-Zeinah: ASH Publishes 2026 Guidelines for Myelofibrosis Management in Blood Advances
-
Oct 17, 2026, 03:48Tristan Siokos: Why Vascular Occlusion Is More Than Just Clots – Breakdown of the 8 Pathways
-
Oct 17, 2026, 02:36Archil Jaliashvili: Oxygen Transport in Capillaries
-
Oct 17, 2026, 02:35Carly Newton: Understanding Access to Red Blood Cell Exchange for People Living With SCD
-
Oct 17, 2026, 02:34Raising Awareness of Blood Clots During and After Pregnancy – Thrombosis UK
-
Oct 17, 2026, 02:33Alaa Salamat: Our Research Accepted for Publication at ASH 2026
-
Oct 17, 2026, 02:32Mohammed Al Sharif: Discussing Factor XIII Testing and Its Clinical Significance
-
Oct 17, 2026, 02:31Joanna Popiolek-Kalisz: Talking about Novel Pharmacotherapy for Hypertension at CV Prevention and Intervention